Trial Profile
Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 04 Jan 2022 Status changed from active, no longer recruiting to completed.
- 13 Jan 2014 New trial record